(Reuters) – Eli Lilly and Co said on Tuesday it has signed an agreement with the Canadian government to supply 26,000 doses of its antibody drug to treat COVID-19 patients for $32.5 million.
The treatment, bamlanivimab, which was developed in partnership with Canadian biotech company AbCellera, will be supplied to Canada over a three-month period between December and February.
The drugmaker said additional doses will be supplied to Canada on a monthly basis according to the medical need of the country and the availability of supply.
Last week, Canada granted an interim authorization to bamlanivimab for treating COVID-19 in patients who are not hospitalized but are at risk of serious illness because of their age or other conditions.
(Reporting by Dania Nadeem in Bengaluru; Editing by Amy Caren Daniel)
